BioPharma « Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 73 74 » | Laatste
[verwijderd]
0
messages.finance.yahoo.com/Stocks_%28...

sfda- timeline

Article 150 of the Amended Measures sets forth clear and speedier timelines for reviewing new drug applications:

1) 90 days for new drug clinical trial applications and 80 days for those entitled to special approval.
2) 150 days for new drug manufacture applications and 120 days for those entitled to special approval.
3) 160 days for applications for drugs already marketed, but with a changed dosage form or generic drugs.
4) 40 days for supplementary applications requiring technical review.

After the technical review has been completed, SFDA is to determine whether to approve an application within 20 days.

Imported drugs are to be reviewed under timelines taking the above as reference points.

209.85.165.104/search?q=cache:YxbbjYx...
[verwijderd]
0
Wow ! met 20000 stuks plots even naar 0.175 en dan terug naar de dagkoers van 0.12/0.13 Die koper is goed belazerd.
[verwijderd]
0
Wat is belazerd,dit kan alleen gebeuren bij bestens orders.
En uhh,als we een koers sprong gaan krijgen maakt die 5 cent ook het verschil niet,wel dan?
Vindt alleen de omzetten wel teleurstellend.
gustaaf1e
0
Ja, de omzetten mogen wel omhoog. Nu wordt de koers soms met 1000 stukjes (= $130) meer dan 5% gewijzigd. Maar iha algemeen lijkt het er nu wel op dat de aandeeltjes worden vastgehouden.
G
gustaaf1e
0
[verwijderd]
0
Calypte Unveils Aware Messenger(TM), an Oral Specimen Collection Device Developed Especially for High-Throughput Testing Laboratories

PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 30, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today launched its latest new product, Aware Messenger(TM), an oral fluid sample collection device for collecting high-quality oral fluid specimens for high-throughput laboratory testing.

"We developed the Aware Messenger(TM) device in response to inquiries from several of our U.S. and international customers who requested a safe, simple and cost-effective alternative to currently marketed sampling devices. In addition, the device will meet the sample collection needs of potential customers who are seeking an alternative to blood testing but still prefer the advantages of high volume batch testing provided by traditional diagnostic methods such as EIA," stated Roger I. Gale, Calypte's President and CEO. "Aware Messenger(TM) is consistent with our growing product line which is aimed at improving the ease with which sample collection and testing can occur." Calypte Biomedical currently markets several diagnostic tests for HIV under the Aware(TM) brand outside the U.S. including its Aware(TM) HIV-1/2 OMT rapid oral fluid test.

According to Dr. Ronald W. Mink, Calypte's Chief Science Officer, "This product provides an exciting new opportunity for Calypte in the laboratory based diagnostics business. The Aware Messenger(TM) sample buffer is specifically formulated to promote sample stability and compatibility with the widest range of clinical laboratory tests. We believe that our tasteless swab, pre-designed for compatibility with conventional clinical assays, and providing a speedy collection without the need for additional processing at the laboratory, constitutes a significant competitive advantage in the oral specimen collector market. Further, we anticipate that users will find Aware Messenger(TM) to be ideally suited for the collection of oral fluid specimens containing antibodies and analytes of interest and will find that it provides excellent specimen stability, even at non-refrigerated temperatures. The design of the Aware Messenger(TM) product provides great potential for current and future expansion into diagnostic product opportunities in the U.S. and international markets."

The Aware Messenger(TM) oral fluid sample collection device uses an untreated, soft, tasteless swab and takes only 15-20 seconds to collect a sample rich in oral mucosal transudate. The device yields a large quantity of sample that is ready for testing without additional processing by the testing laboratory either immediately upon receipt or at a later time at a remote testing laboratory.

Collecting a sample with the Aware Messenger(TM) device involves a simple back and forth wipe of the upper and lower gum line with a swab, which is then placed into a buffer tube. The swab is expressed into the tube and discarded immediately after use. The tube containing the sample can then be delivered to the laboratory where the sample can be immediately and directly used in a suitably validated assay without processing, or stored for batch testing at a later time.

The current device is generic and will require validation by the user for each individual application for diagnostic use by the laboratory. A constantly growing body of literature supports the use of oral fluid specimens as an accurate alternative to blood for the testing for antibodies, antigens, drugs, and genetic testing. Aware Messenger(TM) will be available for shipment in February 2008 in boxes of 50 devices. Additional information about Aware Messenger(TM) can be found on Calypte's website (http://www.calypte.com).


P.
gustaaf1e
0
quote:

GhosTWolF schreef:

het centje erbij zal morgen zijn..
vandaag gesloten op 14
Zelfs 2 centjes in één dag erbij.
+14,2%.
G
[verwijderd]
0
voorlopig gaat het inderdaad goed zo.
De stijging is weer in gang gezet.
De goed-nieuwsshow gaat beginnen.
[verwijderd]
0
Goed nieuws volgt elkaar nu in hoog tempo op. Weer een centje erbij! Het wordt nog wat.

Fox
gustaaf1e
0
[verwijderd]
0
Heen en weer .................. heen en weer!

Ik word er toch wel een beetje verdrietig van!

Weekend!

Fox
ludwig mack
0
ik volg het fonds nu en ik denk dat het hoge aantal aandelen niet bevordelijk is voor een stijging, die je had moeten verwachten na die twee nieuwsfeiten ........
[verwijderd]
0
Het begin is er!!

Calypte Biomedical Completes First Sale of Aware(TM) HIV-1/2 OMT Rapid Oral Fluid Test in India

PORTLAND, Ore.--(BUSINESS WIRE)--Feb. 6, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced the first sale of its Aware(TM) HIV-1/2 OMT rapid oral fluid test in India. The tests were purchased by one of the paramilitary forces of the Government of India.

Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "This sale marks a major milestone for us both as our first sale in India and as our entry into the Indian governmental market. Our Aware(TM) oral fluid test is ideally suited for large institutions such as India's paramilitary forces which need to protect the welfare of their workforces." Mr. Gale continued, "We applaud the Government of India's ambitious plans to combat HIV/AIDS. We believe that the safety and ease of use of non-invasive tests such as our Aware(TM) HIV-1/2 OMT will be instrumental in containing costs and improving efficiencies as India scales up its testing initiatives. Calypte's Aware(TM) HIV-1/2 OMT test is the first and currently only oral fluid test approved in India."

Sujata Mital, Director of Sumit Biosciences Pvt. Ltd., Calypte's distributor in India, stated, "India's paramilitary forces have a vested interest in guarding the health and welfare of their personnel. These personnel are highly trained and make important contributions to guarding India's security. Non-invasive testing will help India's paramilitary organizations safeguard their commitment to and investment in human capital. Further, the experience with non-invasive testing gained by these organizations will concretely demonstrate the advantages of oral fluid testing."

About India's HIV Program

India recently embarked on its Third National AIDS Control Program (NACP-III) with the overall goal of halting and reversing its HIV/AIDS epidemic. Since India's reported prevalence rate remains well below 1%, the major focus of NACP-III will be on scaling up prevention and control initiatives. According to The World Bank Project Appraisal Document on NACP-III, India; dated March 22, 2007, of the US $2.6 billion budgeted over five years for NACP-III, over US $1.8 billion has been allocated to scaling up prevention efforts. One of the major goals cited for NACP-III is increasing the number of people tested from 3 million in 2006 to 22 million by 2011.

P.

[verwijderd]
0
1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 73 74 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
907,65  -3,69  -0,40%  10:11
 Germany40^ 22.764,90 -1,06%
 BEL 20 4.409,33 -1,34%
 Europe50^ 5.413,85 -1,00%
 US30^ 42.355,60 -1,04%
 Nasd100^ 19.945,30 -1,20%
 US500^ 5.704,19 -1,11%
 Japan225^ 36.693,80 -1,58%
 Gold spot 2.904,69 -0,18%
 EUR/USD 1,0817 -0,30%
 WTI 67,01 +0,03%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Eurocommercia... +2,53%
OCI +2,01%
VASTNED +1,81%
THEON INTERNAT +1,36%
Basic-Fit +1,30%

Dalers

EBUSCO HOLDING -7,32%
CM.COM -2,78%
Pharming -2,64%
PROSUS -2,54%
Aperam -2,19%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront